Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ:CTNM) — Market Cap & Net Worth
Market Cap & Net Worth: Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ:CTNM) has a market capitalization of $405.78 Million ($405.78 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13503 globally and #3209 in its home market, demonstrating a 7.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Contineum Therapeutics, Inc. Class A Common Stock's stock price $12.40 by its total outstanding shares 32723877 (32.72 Million). Review Contineum Therapeutics, Inc. Class A Com balance sheet liabilities to assess the company's total debt and financial obligations.
Contineum Therapeutics, Inc. Class A Common Stock Market Cap History: 2024 to 2026
Contineum Therapeutics, Inc. Class A Common Stock's market capitalization history from 2024 to 2026. Data shows change from $480.55 Million to $405.78 Million (-10.94% CAGR).
Index Memberships
Contineum Therapeutics, Inc. Class A Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.02% | #354 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #1302 of 3165 |
Weight: Contineum Therapeutics, Inc. Class A Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Contineum Therapeutics, Inc. Class A Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Contineum Therapeutics, Inc. Class A Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CTNM by Market Capitalization
Companies near Contineum Therapeutics, Inc. Class A Common Stock in the global market cap rankings as of June 17, 2026.
Key companies related to Contineum Therapeutics, Inc. Class A Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Contineum Therapeutics, Inc. Class A Common Stock Historical Marketcap From 2024 to 2026
Between 2024 and today, Contineum Therapeutics, Inc. Class A Common Stock's market cap moved from $480.55 Million to $ 405.78 Million, with a yearly change of -10.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $405.78 Million | +8.49% |
| 2025 | $374.03 Million | -22.17% |
| 2024 | $480.55 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Contineum Therapeutics, Inc. Class A Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $405.78 Million USD |
| MoneyControl | $405.78 Million USD |
| MarketWatch | $405.78 Million USD |
| marketcap.company | $405.78 Million USD |
| Reuters | $405.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibr… Read more